Genvor Inc SEC Filings

Genvor Incorporated appointed Donald Kalkofen as Chief Financial Officer effective May 18, 2026, initially via a services agreement with Wave Financial Consulting LLC that was amended and restated on May 21, 2026.

Mr. Kalkofen is an experienced biotech CFO with more than 20 years of finance leadership and public company and IPO experience. His amended agreement provides $6,250 in monthly cash compensation and $7,750 in deferred monthly cash compensation through 2026, with cash compensation increasing to $14,000 per month starting January 1, 2027. He is eligible for ten-year options to purchase up to 575,000 shares of common stock, subject to Board approval of an equity plan, shareholder approval, and the effectiveness of a Form S-8 registration statement before the options become exercisable.

Genvor Incorporated reported another pre-revenue quarter and highlighted serious liquidity risks. For the three months ended March 31, 2026, the company generated no revenue and posted a net loss of $429,567, widening from $298,983 a year earlier. For the six-month period, the net loss was $1,005,847, a sharp improvement from $5,300,234 mainly because prior-year stock-based CEO compensation was much higher.

At March 31, 2026, Genvor held only $94,808 in cash, had a working capital deficit of $891,095 and an accumulated deficit of $27,199,153. Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern and plans to rely on additional financings.

During the first half of fiscal 2026, Genvor raised $665,333 through common stock and pre-funded warrant issuances, helping fund operating cash outflows of $594,213. Subsequent to quarter-end, it signed a securities purchase agreement with Evergreen Capital for a convertible note of up to $800,000 and warrants for up to 600,000 shares, and entered a non-binding MOU with Canlab International™ to explore peptide-based products for human health markets.

Genvor Incorporated created a new Series C Preferred Stock class and issued one share under an existing advisory agreement. On May 5, 2026, the company filed a certificate of designation in Nevada setting aside four shares as Series C Preferred Stock with a par value of $0.001 per share.

These shares carry standard voting and dividend rights but preferential conversion rights into common stock. Each Series C share may convert, at the holder’s option, into common stock based on a $300,000 value divided by a specified market price formula that depends on whether Genvor is listed on a national exchange by April 14, 2027. On May 8, 2026, one Series C share was issued to Brio Advisory Group LLC as consideration under an advisory agreement, relying on a private offering exemption from registration.

Genvor Incorporated entered a securities purchase agreement with Evergreen Capital Management LLC, issuing a convertible promissory note of up to $800,000 and warrants to buy up to 600,000 common shares for a purchase price of up to $666,668, paid in four tranches.

The note carries 10% annual interest, matures the earlier of nine months from the April 15, 2026 issue date or an Exchange Listing, and is generally convertible at $1.00 per share, with a lower default conversion formula and a 4.99% beneficial ownership cap. The five-year cashless warrants have a $1.00 initial exercise price, adjustable to the note’s conversion price.

Genvor also signed an Advisory Agreement with Brio Advisory Group, under which Brio provides strategic and financing advice in exchange for preferred stock valued at $300,000 per funding tranche, or equivalent common stock if no Exchange Listing occurs within one year, subject to a minimum $1.00 per-share valuation.

Genvor Inc. reported that Chief Executive Officer Chad Lee Pawlak Sr. received a grant of 250,000 shares of common stock at $0.50 per share. According to the disclosure, this stock award compensates Mr. Pawlak for converting $125,000 of outstanding payables owed to him by the company under a restructured compensation package approved by the board as of December 20, 2024. Following this grant, he directly holds 7,000,000 shares of Genvor common stock.

Pawlak Chad Lee Sr. reported acquisition or exercise transactions in this Form 4 filing.

Genvor Inc Chief Executive Officer Chad Lee Pawlak Sr. received a grant of 250,000 shares of Common Stock as compensation, with a reported price of $0.0000 per share. After this award, he directly holds 6,750,000 Common Stock shares.

The footnote explains this is a compensation award for January–March 2026 under a restructured compensation package approved by the Board of Directors as of December 20, 2024.

Genvor Incorporated reported another quarterly loss and highlighted serious liquidity risks while filing an amendment to correct cover-page checkboxes. For the three months ended December 31, 2025, the company generated no revenue and posted a net loss of $576,280, a sharp improvement from $5,001,251 a year earlier as stock-based compensation and overall operating expenses declined.

Cash was $103,580 at December 31, 2025 with a working capital deficit of about $1.06M, and management stated that these conditions raise substantial doubt about Genvor’s ability to continue as a going concern. To fund operations, the company relied on issuing equity for cash, services, debt conversions, and warrant exercises, bringing common shares to 34,434,938 outstanding as of February 11, 2026.

Genvor Incorporated reported another loss-making quarter with no revenue for the three months ended December 31, 2025. The company generated no sales while cutting its net loss to about $576,000 from roughly $5.0 million a year earlier, mainly due to much lower compensation and stock-based expenses.

Cash increased to about $103,580, helped by $260,000 raised from common stock sales, but Genvor still had a working capital deficit of roughly $1.06 million and an accumulated deficit of about $26.8 million. Management disclosed that these recurring losses, negative cash flow and limited cash raise substantial doubt about the company’s ability to continue as a going concern.

The share count continued to rise, reaching 34.43 million common shares outstanding at December 31, 2025, plus significant convertible preferred stock and warrants that could add further dilution. Much of Genvor’s obligations, including salary and advances, are owed to its CEO and scientific advisors, who earn 8% interest and can convert accrued amounts into stock, tying liquidity and dilution closely to related-party arrangements.

Genvor Inc. reported that its Chief Executive Officer, director, and 10% owner, Chad Lee Pawlak Sr., received a stock compensation award of 250,000 shares of common stock on January 9, 2026. The shares were acquired at a stated price of $0.00 per share, reflecting an equity grant rather than an open-market purchase.

Following this award, Pawlak beneficially owned 6,500,000 shares of Genvor common stock directly. According to the filing, this grant represents compensation for the period from October through December 2025 under a restructured compensation package approved by the company’s board of directors on December 20, 2024.